If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences [The Motley Fool]
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: The Motley Fool
If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences The rise of biosimilars, the name given to generic versions of biologic drugs such as monoclonal antibodies and granulocyte colony-stimulating growth factors, hasn't quite lived up to the hype in recent years. The U.S. Food and Drug Administration (FDA) has approved biosimilars, but many haven't made it to the market yet. Some of the companies that have launched balked at offering payer discounts and rebates, which can sometimes make the copycat drugs more expensive than the innovator drugs they aspire to replace. And doctors sometimes hesitate to switch patients to biosimilars because they technically aren't exact copies of innovator drugs (proteins are more difficult to exactly replicate than small molecule drugs produced with chemistry). But Coherus BioSciences NASDAQ:CHRS small-cap stock Image source: Getty Images. A surprisingly smooth trajectory Commercializing a new biosimilar isn't easy. Companies have
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years [Yahoo! Finance]Yahoo! Finance
- Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual MeetingGlobeNewswire
- Coherus Biosciences: Dumping One Drug But Showing Promise With Another [Seeking Alpha]Seeking Alpha
- Coherus BioSciences, Inc. (NASDAQ: CHRS) had its price target lowered by analysts at HC Wainwright from $13.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
CHRS
Earnings
- 3/13/24 - Miss
CHRS
Analyst Actions
- 3/18/24 - HC Wainwright
CHRS
Sec Filings
- 4/15/24 - Form ARS
- 4/15/24 - Form DEFA14A
- 4/15/24 - Form DEF
- CHRS's page on the SEC website